(CercleFinance.com) – Eli Lilly and Company presented the five-year results of a phase 3 study that evaluated for two years the administration of Verzenio® (abemaciclib) associated with endocrine therapy (ET) compared to ‘ET alone in patients with HR+, HER2-, node-positive early breast cancer (EBC) at high risk of recurrence.
“These five-year data clearly demonstrate a persistent effect beyond the end of two years of treatment with abemaciclib,” assures Nadia Harbeck, MD, Ph.D, director of the Breast Center and chair of the Conservative Oncology, Department of OB&GYN, LMU University Hospital (Munich, Germany).
These data were shared during a late-breaking presentation at the 2023 European Society of Medical Oncology (ESMO) Congress.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
